First year of Back-UP Project: the consortium meets in Enschede, The Netherlands

27 December 2018

Roessingh Research and Development (RRD) hosts the 12th month project meeting in this charming Dutch city 


Back-UP has completed the first year of intense activity, and celebrates its consortium meeting in Enschede.

BackUP logo gran

Roessingh Research and Development Roessingh Research and Development (RRD) is the biggest centre in the Netherlands where a wide range of disciplines such as rehabilitation medicine, movement sciences, psychology, physiotherapy, biomedical sciences and computer sciences work together under a single roof for current and future innovations in rehabilitation and chronic care.

As an internationally recognised scientific research institute, RRD has a unique position between the university and healthcare practice.
The partners visited also the Roessingh Centrum voor Revalidatie and the NOVALAB, which has a completely new innovative treatment room with a great variety of rehabilitation technology and telemedicine applications, including a 3D rehabilitation treatment experimental application using virtual reality.

Once in the room, the focus was on the project. “We are confident about the future” states the project coordinator Helios de Rosario.

The aim of Back-UP project is to create a prognostic model to support more effective and efficient management of Neck and Low Back Pain (NLBP), based on the digital representation of multidimensional clinical information, and in-silico assessments of possible interventions.

BACKUP imagen web

Management of NLBP is a difficult challenge for healthcare professionals and prevention services in this field, since their decisions have a decisive impact on the patient’s future health and welfare, as well as on the economic burden on the public and private healthcare systems.

The meeting lasted two days. On day one, all the work packages status was deeply analysed. Day two was mostly dedicated to preparing the forthcoming review meeting: “In July, the consortium will travel to Luxembourg for the first check with EC”, says Giuseppe Caprara, Innovation manager at IBV. “That is why is crucial to set up activities accordingly”, continues de Rosario.

In the meantime, the consortium had two important line-up changes: Università di Parma ended its participation in the project, and the research group of the University of Sheffield has moved to the University of Leeds. At the moment these changes are under amendment.

During the meeting, Milton Hoz from Sheffied/Leeds, presented the progress in the creation of the system architecture, which is part of work package 5 of the project. “There is a prototype for beta testing already available”, says Hoz. Additionally, a paper around this topic has been published in the IEEE Conference on Bioinformatics and Biomedicine.

Also a first version of the baseline questionnaire has been presented. This will be used to define the recommended treatments after the registration of the patient, and its final version is expected to be ready in January.

Next consortium meeting will be in June in Croatia, hosted by GENOS with his third party PMFST (University of Split).

Besides above mentioned IBV (Project Coordinator), RRD, GENOS and PMFST, other partners are: GMV Soluciones Globales Internet SAU and MAZ Mutua De Accidentes De Trabajo Y Enfermedades Profesionales De La Seguridad Social Nº11 (Spain); CIOP-POB Centralny Instytut Ochrony Pracy - Panstwowy Instytut Badawczy (Poland); The University Of Leeds and University Of Keele (UK); Norges Teknisk-Naturvitenskapelige Universitet (Norway); Karolinska Institutet (Sweden); Università degli Studi Di Padova (Italy) and EMPIRICA Gesellschaft Fuer Kommunikations- Und Technologie Forschung Mbh (Germany)

For more information, visit


This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 777090.




  • Universitat Politècnica de València · Camino de Vera s/n · 46022 · Valencia · España
  • +34 96 111 11 70 / +34 610 567 200
  • +34 96 387 91 69
  • This email address is being protected from spambots. You need JavaScript enabled to view it.

IBV News


Este sitio web utiliza cookies propias y de terceros para su funcionamiento, para mantener la sesión y personalizar la experiencia del usuario, así como para obtener estadísticas anónimas de uso de la web. Para más información sobre las cookies utilizadas consulta nuestra poítica de cookies.